Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) was upgraded by Wall Street Zen to a “sell” rating in a report issued on Friday.
Salarius Pharmaceuticals Stock Up 8.5%
NASDAQ:SLRX opened at $5.77 on Friday. The firm has a market cap of $2.94 million, a PE ratio of -0.13 and a beta of 0.45. Salarius Pharmaceuticals has a 12 month low of $4.76 and a 12 month high of $108.00. The company’s 50-day moving average price is $10.94 and its two-hundred day moving average price is $13.27.
Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($33.00) by $32.55.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
Featured Articles
- Five stocks we like better than Salarius Pharmaceuticals
- 3 REITs to Buy and Hold for the Long Term
- Royal Caribbean Earnings Beat Fuels Strong 2025 Outlook
- Using the MarketBeat Stock Split Calculator
- Alphabet’s Breakout Potential: From Laggard to AI Leader
- Growth Stocks: What They Are, Examples and How to Invest
- TJX Stock Price Hits Fresh High, Signals More Highs to Follow
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
